Alantra advised Amethyst Radiotherapy in the context of a capital increase by The Rohatyn Group
ServiceStrategic Advisory; M&A
Vienna – Alantra, the global investment banking and asset management firm, has advised Amethyst Radiotherapy, a leading operator of oncology radiotherapy clinics across Europe, in the context of a capital increase by The Rohatyn Group, a US-based global Emerging Markets investor.
Amethyst is a pan-European provider of radiotherapy services for cancer care, operating 10 centers across Romania, Poland, Austria, France and Italy. Alantra advised Amethyst on this transaction, mediating between key stakeholders in order to ensure an unwinding of previous investors’ participations in the company and thereby allowing the entry of The Rohatyn Group into the capital structure.
Ludovic Robert, founding shareholder of Amethyst, commented: “We were impressed with Alantra’s effort to reconcile the positions of stakeholders in the company in order to allow it to continue its successful strategy of growth and internationalization”.
Klaus Vukovich, Managing Partner at Alantra Austria & CEE added: “It was a pleasure working with all parties involved and we are delighted to have helped a pan-European champion move to the next level of growth, providing state-of-the-art treatments to oncology patients across the continent”.
The investment will be used to accelerate the growth of the Company across Europe through the roll-up of clinics, the development of greenfield centers and outsourcing partnerships with hospitals.
Founded in 2002, The Rohatyn Group is an emerging markets focused asset management firm headquartered in New York, with offices around the globe including London, Boston, Singapore, Rotorua, Mumbai, New Delhi, Buenos Aires, Montevideo, Lima and São Paulo.
Dec 2021Growth investmentDec 2021SECTOR HealthcareService Strategic Advisory
Dec 2021Debt Capital MarketsValue €230 millionDec 2021SECTOR HealthcareService Debt AdvisoryValue €230 million
Nov 2021Private placement and Equity raisingNov 2021SECTOR HealthcareService Equity Capital Markets
Nov 2021Sell-side advisoryValue $47.4 millionNov 2021SECTOR HealthcareService M&AValue $47.4 million